Table 1.
Patient characteristics, metastatic sites, survival times, and therapies used
| Case | Age, years;* sex | Metastatic sites | Survival from initial diagnosis of primary melanoma (years) | Survival with metastatic disease (years) | Stage IIIC/IV | Status | Therapies used | ||
|---|---|---|---|---|---|---|---|---|---|
| A | 48; M | Spleen, brain, LN, SC, bone | 14 | 11 | IV | Alive | Surgical excision, radiotherapy, C-Vax, VMCL | ||
| B | 64; F | LN, SC, bone | 10 | 7 | IV | Alive | Surgical excision, ILI, VMCL, Provectus, DTIC, fotemustine | ||
| C | 57; M | LN, lungs, SC, liver, bone | 6 | 3 | IV | Dead | Amputation, surgical excision, DTIC, fotemustine, cyclophosphamide | ||
| D | 58; M | Liver, scalp | 13 | 13 | IV | Alive | Surgical excision | ||
| E | 45; M | Eye, SC, lungs, kidney, brain, LN, colon, liver | 9 | 8 | IV | Dead | Surgical excision, fotemustine, VMCL, radiotherapy | ||
| F | 60; M | SC, lungs, brain, meninges, gallbladder, adrenal gland, epicardium, peritoneum, muscle, bone | 6 | 6 | IV | Dead | Surgical excision, VMCL, DTIC, fotemustine | ||
| G | 59; M | SC, lung, LN, colon | 14 | 12 | IV | Alive | Surgical excision, radiotherapy, VMCL | ||
| H | 41; F | LN, SC, lungs, liver, spleen, bone, kidney | 26 | 14 | IV | Alive | Surgical excision, C-Vax, DTIC, VMCL, ILI, radiotherapy | ||
| I | 49; M | LN, SC | 14 | 13 | INC | Alive | Surgical excision, VMCL | ||
| J | 33; M | LN, SC | 19 | 14 | INC | Alive | Surgical excision | ||
| K | 34; M | LN, SC, lung | 15 | 15 | IV | Alive | Surgical excision, radiotherapy | ||
| L | 51; M | SC, lung | 18 | 11 | IV | Alive | Surgical excision | ||
| M | 48; M | LN | 13 | 13 | INC | Alive | No treatment | ||
| N | 56; F | LN | 20 | 10 | INC | Alive | Surgical excision, ILI, VMCL | ||
| O | 79; M | LN, parotid gland, SC | 6 | 6 | IV | Alive | Surgical excision | ||
| P | 71; F | SC, LN | 14 | 12 | INC | Alive | Surgical excision, ILI, VMCL | ||
| Q | 54; M | Brain, SC, LN, bowel | 9 | 9 | IV | Alive | Surgical excision, radiotherapy | ||
| R | 83; M | SC | 6 | 6 | INC | Alive | Surgical excision, radiotherapy | ||
| Median (years) | 55 | 13.5 | 11 | ||||||
Note:
*
Age at diagnosis of metastatic disease.
Abbreviations: M, male; F, female; LN, lymph node; SC, subcutaneous; C-Vax, Canvaxin or Cancer Vax; VMCL, vaccinia melanoma cell lysate vaccine; ILI, isolated limb infusion chemotherapy; DTIC, dacarbazine.